公开(公告)号：US20240101549A1

公开(公告)日：2024-03-28

申请号：US18257123

申请日：2021-12-16

Applicant: AstraZeneca AB

Inventor： Jonas BRÅNALT ,  Björn HOLM ,  Maria JOHANSSON ,  Olle KARLSSON ,  Daniel Laurent KNERR ,  Anneli NORDQVIST ,  Robert John SHEPPARD ,  Marianne SWANSON ,  Anna TOMBERG

IPC: C07D417/14 ,  C07D493/10 ,  C07D487/04 ,  C07D491/107 ,  C07D491/113 ,  C07D487/10 ,  C07D498/08 ,  C07D495/10 ,  A61P1/16

CPC classification number: C07D417/14 ,  C07D493/10 ,  C07D487/04 ,  C07D491/107 ,  C07D491/113 ,  C07D487/10 ,  C07D498/08 ,  C07D495/10 ,  A61P1/16

Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

公开(公告)号：US20230312550A1

公开(公告)日：2023-10-05

申请号：US18332897

申请日：2023-06-12

Applicant: AstraZeneca AB

Inventor： Jonas BRÅNALT ,  Björn HOLM ,  Maria JOHANSSON ,  Olle KARLSSON ,  Daniel Laurent KNERR ,  Anneli NORDQVIST ,  Robert John SHEPPARD ,  Marianne SWANSON ,  Anna TOMBERG

IPC: C07D417/12 ,  A61P1/16

CPC classification number: C07D417/12 ,  A61P1/16

Abstract: Compounds having the structure of Formula (I):




and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.